Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function

Human Molecular Genetics

Volumn 22, Issue 13, 2013, Pages 2626-2633

  Pitcher, Meagan R ^a,b   Ward, Christopher S ^a,b   Arvide, E Melissa ^a   Chapleau, Christopher A ^c   Pozzo Miller, Lucas ^c   Hoeflich, Andreas ^d   Sivaramakrishnan, Manaswini ^e   Saenger, Stefanie ^e   Metzger, Friedrich ^e   Neul, Jeffrey L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c University of Alabama at Birmingham   (United States)

^d LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MACROGOL; METHYL CPG BINDING PROTEIN 2; SOMATOMEDIN C;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BODY PLETHYSMOGRAPHY; BREATHING; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERINSULINEMIA; INSULIN LIKE ACTIVITY; INSULIN TREATMENT; LIFESPAN; LOW DRUG DOSE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REST; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; HEART RATE; HYPERINSULINISM; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; MALE; METABOLIC SYNDROME X; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, KNOCKOUT;

ANIMALIA; MUS;

EID: 84878912163     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt111     Document Type: Article

References (39)

1. Laurvick, C.L., de Klerk, N., Bower, C., Christodoulou, J., Ravine, D., Ellaway, C., Williamson, S. and Leonard, H. (2006) Rett syndrome in Australia: a review of the epidemiology. J. Pediatr., 148, 347-352.
2. Neul, J.L., Kaufmann, W.E., Glaze, D.G., Christodoulou, J., Clarke, A.J., Bahi-Buisson, N., Leonard, H., Bailey, M.E., Schanen, N.C., Zappella, M. et al. (2010) Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol., 68, 944-950.
3. Glaze, D.G. (2005) Neurophysiology of Rett Syndrome. J. Child Neurol., 20, 740-746.
4. Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U. and Zoghbi, H.Y. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet., 23, 185- 188.
5. Neul, J.L., Fang, P., Barrish, J., Lane, J., Caeg, E.B., Smith, E.O., Zoghbi, H., Percy, A. and Glaze, D.G. (2008) Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett Syndrome. Neurology, 70, 1313-1321.
6. Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J. and Zoghbi, H.Y. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science, 320, 1224-1229.
7. Tropea, D., Giacometti, E., Wilson, N.R., Beard, C., McCurry, C., Fu, D.D., Flannery, R., Jaenisch, R. and Sur, M. (2009) Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. PNAS, 106, 2029- 2034.
8. Chen, R.Z., Akbarian, S., Tudor, M. and Jaenisch, R. (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet., 27, 327-331.
9. Kline, D.D., Ogier, M., Kunze, D.L. and Katz, D.M. (2010) Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J. Neurosci., 30, 5303-5310.
10. Larimore, J.L., Chapleau, C.A., Kudo, S., Theibert, A., Percy, A.K. and Pozzo-Miller, L. (2009) Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobio. of Disease, 34, 199-211.
11. Chang, Q., Khare, G., Dani, V., Nelson, S. and Jaenisch, R. (2006) The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron, 49, 341-348.
12. Ricciardi, S., Boggio, E.M., Grosso, S., Lonetti, G., Forlani, G., Stefanelli, G., Calcagno, E., Morello, N., Landsberger, N., Biffo, S. et al. (2011) Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Gen., 20, 1182-1196.
13. Ward, C.S., Arvide, E.M., Huang, T.W., Yoo, J., Noebels, J.L. and Neul, J.L. (2011) MeCP2 is critical within HoxB1-derived tissues of mice for normal lifespan. J. Neurosci., 31, 10359-10370.
14. Metzger, F., Sajid, W., Saenger, S., Staudenmaier, C., van der Poel, C., Sobottka, B., Schuler, A., Sawitzky, M., Poirier, R., Tuerck, D. et al. (2011) Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J. Bio. Chem., 286, 19501-19510.
15. Saenger, S., Goeldner, C., Frey, J.R., Ozmen, L., Ostrowitzki, S., Spooren, W., Ballard, T.M., Prinssen, E., Borroni, E. and Metzger, F. (2011) PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm. IGF Res., 21, 292-303.
16. Heald, A.H., Kaushal, K., Siddals, K.W., Rudenski, A.S. Anderson, S.G. and Gibson, J.M. (2006) Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes, 114, 371-376.
17. Jablonka, S., Holtmann, B., Sendtner, M. and Metzger, F. (2011) Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motorneuron disease. Exp. Neurol., 232, 261-269.
18. Guy, J., Hendrich, B., Holmes, M., Martin, J.E. and Bird, A. (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet., 27, 322-326.
19. Stearns, N.A., Schaevitz, L.R., Bowling, H., Nag, N., Berger, U.V. and Berger-Sweeney, J. (2007) Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neurosci., 146, 907- 921.
20. Banks, W.A., Jaspan, J.B. and Kastin, A.J. (1997) Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides, 18, 1257-1262.
21. Lonetti, G., Angelucci, A., Morando, L., Boggio, E.M., Giustetto, M. and Pizzorusso, T. (2010) Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol. Psychiatry, 67, 657-665.
22. Kassi, E., Pervanidou, P., Kaltsas, G. and Chrousos, G. (2011) Metabolic syndrome: definitions and controversies. BMC Med., 9, 13-48.
23. Kuroda, A., Rauch, T.A., Todorov, I., Ku, H.T., Al-Abdullah, I.H., Kandeel, F., Mullen, Y., Pfeifer, G.P. and Ferreri, K. (2009) Insulin gene expression is regulated by DNA methylation. PloS One, 4, e6953.
24. Fiorentini, A., Perciaccante, A., Valente, R., Paris, A., Serra, P. and Tubani, L. (2010) The correlation among QTc interval, hyperglycaemia and the impaired autonomic activity. Auton. Neurosci. 154, 94-98.
25. Pickham, D., Helfenbein, E., Shinn, J.A., Chan, G., Funk, M., Weinacker, A., Liu, J.N. and Drew, B.J. (2012) High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Critical Care Med., 40, 394- 399.
26. van Noord, C., Sturkenboom, M.C., Straus, S.M., Hofman, A., Kors, J.A., Witteman, J.C. and Stricker, B.H. (2010) Serum glucose and insulin are associated with QTc and RR intervals in nondiabetic elderly. Eur. J. Endocrinol., 162, 241-248.
27. McCauley, M.D., Wang, T., Mike, E., Herrera, J., Beavers, D.L., Huang, T.W., Ward, C.S., Skinner, S., Percy, A.K., Glaze, D.G. et al. (2011) Pathogenesis of lethal cardia arrhythmias in Mecp2 mutant mice: implication for therapy in Rett Syndrome. Sci. Transl. Med., 3, 113ra125.
28. Corvin, A.P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D.W. and Tropea, D. (2012) Insulin-like growth factor 1 (IGF1) and its active peptide (1-3) IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci. Lett., 520, 51-56.
29. Nilsson-Hakansson, L., Civalero, I., Zhang, X., Carlsson-Skwirut, C., Sara, V.R. and Nordberg, A. (1993) Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain. Neuroreport, 4, 1111-1114.
30. Lioy, D., Garg, S., Monaghan, C., Raber, J., Foust, K., Kaspar, B., Hirrlinger, P., Kirchhoff, F., Bissonnette, J., Ballas, N. and Mandel, G. (2011) A role for glia in the progression of Rett's syndrome. Nature, 475, 497-500.
31. Samaco, R.C., Fryer, J.D., Ren, J., Fyffe, S., Chao, H.T., Sun, Y., Greer, J.J., Zoghbi, H.Y. and Neul, J.L. (2008) A partial loss of function allele of Methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum. Mol. Gen., 17, 1718-1727.
32. Wenk, G.L. and Hauss-Wegrzyniak, B. (1999) Altered cholinergic function in the basal forebrain of girls with Rett syndrome. Neuropediatrics, 30, 125-129.
33. Panayotis, N., Pratte, M., Borges-Correia, A., Ghata, A., Villard, L. and Roux, J.C. (2011) Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobio. Dis., 41, 385-397.
34. Hamberger, A., Gillberg, C., Palm, A. and Hagberg, B. (1992) Elevated CSF glutamate in Rett syndrome. Neuropediatrics, 23, 212-213.
35. Lappalainen, R. and Riikonen, R.S. (1996) High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr. Neurol., 15, 213-216.
36. Maezawa, I. and Jin, L.W. (2010) Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci., 30, 5346-5356.
37. Derecki, N.C., Cronk, J.C., Lu, Z., Xu, E., Abbott, S.B., Guyenet, P.G. and Kipnis, J. (2012) Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature, 484, 105-109.
38. Kondo, M., Gray, L.J., Pelka, G.J., Christodoulou, J., Tam, P.P. and Hannan, A.J. (2008) Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome-Mecp2 gene dosage effects and BDNF expression. European J. Neurosci., 27, 3342- 3350.
39. Lacaria, M., Saha, P., Potocki, L., Bi, W., Yan, J., Girirajan, S., Burns, B., Elsea, S., Walz, K., Chan, L. et al. (2012) A duplication CNV that conveys traits reciprocal to metabolic syndrome and protects against diet-induced obesity in mice and men. PLoS Genet., 8, e1002713.